Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- A Record 32 Officials at Drug-related Companies Were Paid Over 100 Million Yen in FY2012; Hiroshi Mitsuhara Was Top-paid Official of a Pharmacy Chain for the 4th Year in a Row
August 16, 2013
- Swiss OKs Schizophrenia Treatment Lurasidone: DSP, Takeda
August 15, 2013
- ViiV Healthcare Wins US Regulatory Approval for Anti-HIV Drug Dolutegravir
August 15, 2013
- Generics of the Major Anticancer Drug TS-1 Launched by Just 2 Companies Due to Development Hurdles
August 15, 2013
- Eisai Paid a Total of 18.7 Billion Yen to Doctors and Medical Institutions, 1.1 Billion Yen for Research Grants
August 14, 2013
- Sitagliptin Filed for Combination Therapy with Glinides: MSD, Ono
August 14, 2013
- Novartis AG to Cease Worldwide Development of Afinitor for Hepatocellular Carcinoma
August 14, 2013
- Chugai Paid 18.1 Billion Yen to Healthcare Professionals in 2012
August 13, 2013
- Novartis’s 11-Year Research Grants to 5 Universities Total 1.1 Billion Yen
August 13, 2013
- JPWA Operating Profit Margin at 0.63%, First Gross Profit Margin Rise Since FY2007
August 13, 2013
- MSD Paid 20.8 Billion Yen to Doctors, Medical Institutions in FY2012
August 13, 2013
- Payments to Healthcare Professionals by 10 Drug Makers Top 150 Billion Yen
August 13, 2013
- Otsuka Holdings’ Pharmaceutical Sales Rise 14.8%, Global Sales for Abilify Up 21.9% in April-June Period
August 12, 2013
- Novartis Corrects Third-Party Investigation Report on Diovan Studies
August 12, 2013
- DSP to Set Up Regenerative & Cellular Medicine Office for Integrated Management of All Related Functions
August 12, 2013
- AZ’s Exenatide Promotion to Break Free from Weight-Loss Image of GLP-1 Receptor Agonists
August 9, 2013
- Ethical Drug Sales Down 0.1% in June: Crecon Report
August 9, 2013
- Seikagaku Obtains Favorable Results from PIII Study of Condoliase for Lumbar Disc Herniation, Plans to File NDA in Japan During FY2013
August 9, 2013
- Meiji Seika Pharma Changes New Drug Plan in the CNS Field; Filing and Launch of Asenapine to Take Priority
August 9, 2013
- Sawai Lifts Limit Restrictions on Atelec Generic Supplies
August 8, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…